Avelas Bio Raises $20M to Push Cancer-Illuminating Biologic Agent
Xconomy
AUGUST 17, 2016
and San Diego’s Avalon Ventures. Stengone said the new funding also will help the company evaluate the use of AVB-620 in other types of cancer surgery, to advance new cancer drugs that rely on Avelas’ proprietary technology, and to expand the company’s current roster of “seven employees and an army of consultants.”.
40 
Let's personalize your content